Does OLAPARIB Cause Agranulocytosis? 11 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Agranulocytosis have been filed in association with OLAPARIB (Lynparza). This represents 0.1% of all adverse event reports for OLAPARIB.
11
Reports of Agranulocytosis with OLAPARIB
0.1%
of all OLAPARIB reports
5
Deaths
5
Hospitalizations
How Dangerous Is Agranulocytosis From OLAPARIB?
Of the 11 reports, 5 (45.5%) resulted in death, 5 (45.5%) required hospitalization, and 1 (9.1%) were considered life-threatening.
Is Agranulocytosis Listed in the Official Label?
Yes, Agranulocytosis is listed as a known adverse reaction in the official FDA drug label for OLAPARIB.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Malignant neoplasm progression (1,862)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
What Other Drugs Cause Agranulocytosis?
CLOZAPINE (1,766)
CYCLOPHOSPHAMIDE (1,242)
RITUXIMAB (1,154)
SULFAMETHOXAZOLE\TRIMETHOPRIM (797)
PANTOPRAZOLE (599)
METHOTREXATE (550)
SODIUM (549)
EPIRUBICIN (491)
METAMIZOLE (438)
DOCETAXEL (436)
Which OLAPARIB Alternatives Have Lower Agranulocytosis Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL